Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. Jama 310 (17): 1842–1850

Delgado-Lopez PD, Corrales-Garcia EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18 (11): 1062–1071

Fianco G, Contadini C, Ferri A, Cirotti C, Stagni V, Barila D (2018) Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma. Int J Mol Sci 19 (12): 3798

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376 (11): 1027–1037

Osuka S, Van Meir EG (2017) Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Investig 127 (2): 415–426

Campos B, Olsen LR, Urup T, Poulsen HS (2016) A comprehensive profile of recurrent glioblastoma. Oncogene 35 (45): 5819–5825

Richardson PJ (2016) CXCR4 and Glioblastoma. Anticancer Agents Med Chem 16 (1): 59–74

Stevenson CB, Ehtesham M, McMillan KM, Valadez JG, Edgeworth ML, Price RR, et al (2008) CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery 63 (3): 560-9; discussion 569–570.

Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, Shigemori M (2011) CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol 28 (2): 89–97

Ehtesham M, Mapara KY, Stevenson CB, Thompson RC (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Letters 274 (2): 305–312

Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, et al (2017) The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol 39 (6): 1010428317695528

Rios A, Hsu SH, Blanco A, Buryanek J, Day AL, McGuire MF, et al (2016) Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. Oncoscience 3 (5–6): 156–163

De Clercq E (2019) Mozobil(R) (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem Chemother 27: 2040206619829382

Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37 (2): 1253–1262

Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, et al (2012) Development of a unique small molecule modulator of CXCR4. PloS one 7 (4): e34038

Liu Y, Zhou J, Pan JA, Mabiala P, Guo D (2014) A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner. Mol Biotechnol 56 (10): 890–902

Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP et al (2007) Discovery of small molecule CXCR4 antagonists. J Med Chem 50(23):5655–5664

Article  CAS  Google Scholar 

Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100 (23): 13513–13518

Weathers SP, de Groot J (2015) VEGF Manipulation in Glioblastoma. Oncology (Williston Park) 29 (10): 720–727

Barone A, Sengupta R, Warrington NM, Smith E, Wen PY, Brekken RA, et al (2014) Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget 5 (20): 9811–9822

Yamaguchi K, Sudo H, Imai K (2019) Vascular endothelial growth factor signaling in VE-cadherin expression and tube-like formation by rheumatoid arthritic synovial fibroblast-like cells. Biochem Biophys Res Commun 508 (2): 405–409